Demystifying breast cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Synergistic bioinformatics and sophisticated machine learning unveil ferroptosis-driven regulatory pathways and immunotherapy potential in breast carcinoma.Discover oncology · 2025
   Article
2. Liposomal Nano-Based Drug Delivery Systems for Breast Cancer Therapy: Recent Advances and Progresses.Anti-cancer agents in medicinal chemistry · 2024
   Review
3. Capturing the True Cost of Breast Cancer Treatment: Molecular Subtype and Stage-Specific per-Case Activity-Based Costing.Current oncology (Toronto, Ont.) · 2023
   Article
4. The family physician: Jack of all trades, master of integration.Canadian family physician Medecin de famille canadien · 2023
   Article
5. Cancer survivorship road map.Canadian family physician Medecin de famille canadien
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as